An Open-label, Randomized, Phase I/II Trial Investigating the Safety and Efficacy of IO102 in Combination With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment for Patients With Metastatic Non-Small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 29 Nov 2019
Price : $35 *
At a glance
- Drugs IO 102 (Primary) ; IO 102 (Primary) ; Pembrolizumab (Primary) ; Carboplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors IO Biotech
- 10 Sep 2019 Trial design presented at the 20th World Conference on Lung Cancer.
- 15 May 2019 According to an IO Biotech media release, phase II portion of the study has been initiated.
- 15 May 2019 According to an IO Biotech media release, this trial is part of a collaborative agreement with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the US and Canada).